Retatrutide Investigated for Kidney Protection in Overweight Patients with CKD

Globally, obesity, Type 2 Diabetes (T2D), and chronic kidney disease (CKD) represent a significant public health burden, often co-occurring and exacerbating each other's progression. CKD affects millions, leading to severe health complications and increased mortality, especially when compounded by metabolic disorders. Current treatments for CKD often focus on managing symptoms or slowing progression, but there's a pressing need for therapies that can simultaneously address underlying metabolic dysfunction and directly protect renal function. This Phase 2b study aims to evaluate if Retatrutide, a novel multi-agonist, can improve kidney health in individuals with overweight or obesity and CKD, regardless of their T2D status.

This Phase 2b study was designed to rigorously evaluate the impact of Retatrutide on key indicators of renal function. While specific results are pending as the study was completed in October 2025, researchers aimed to quantify changes in markers such as estimated glomerular filtration rate (eGFR) and albuminuria, which are crucial for assessing kidney health. The study sought to determine if Retatrutide treatment, administered over 31 weeks, could lead to a statistically significant improvement in these renal parameters compared to placebo. The primary objective was to investigate whether Retatrutide could offer a protective or ameliorative effect on renal function in individuals grappling with overweight or obesity and chronic kidney disease, irrespective of their Type 2 Diabetes status. Secondary objectives likely included assessing the drug's impact on body weight, glycemic control (e.g., HbA1c), and other metabolic markers, which are often intertwined with renal health. The comparative analysis between the active treatment arm and the placebo group is expected to reveal the magnitude of any observed benefits.